Therapeutic area
  • Cancer

What the technology does

LITA is a novel nanoparticle containing short-chain fatty acids, particularly acetate, that alters the metabolic process leading to cancer cell death

Advantage

These nanoparticle are concentrated in tumour cells and by release of acetate change the metabolism in the cancer cell. Cancer cells are vulnerable to metabolic interruption and these nanoparticle seem to selectively cause degradation of cancer cell mitochondria. This results in selective cell death. In fat cells these nanoparticles cause an increase in the number of mitochondria resulting in the “browning” of fat cells which may have potential therapeutic effects.

Main application field

Therapeutic

Usage

Cancer treatment, potential uses in fatty liver disease and other inflammatory indications.

Status

Technology ready for evaluation and licence.

Intellectual Property

Patents filed in Europe, USA, China, Japan, Australia, Canada, Hong Kong WO2014/033453

Offering

Exclusive or non-exclusive licences are available

Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
  • We would love to send you information about LifeArc news and events. Please let us know if you would like us to contact you by selecting one of the following options:
All Licensing Opportunities